Today: 23 June 2026
Browse Category

Pharmaceuticals 19 January 2026 - 22 January 2026

AbbVie is acquiring Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal is expected to close in the third quarter and will bring AbbVie zumilokibart, an experimental long-acting drug for atopic dermatitis and other immune diseases. Apogee claims its top eczema drug could significantly reduce injection frequency compared to Dupixent, with Phase 3 trials planned for this year. Pfizer shares declined over the past week after CFO Dave Denton announced he will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession, execution, and competition from obesity-drug makers. Pfizer’s stock has also been affected by concerns over pricing pressure, patent cliffs, and a longer path to profitability in obesity drugs. Meanwhile, Novo Nordisk shares rose about 5% as healthcare stocks gained favor among investors seeking defensive positions, even as the company reported strong demand for its Wegovy pill. Alumis shares surged 15.55% ahead of Phase 2b lupus results due in the third quarter and a planned psoriasis NDA filing in the fourth quarter. Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected on July 29. Other notable moves include AtaiBeckley’s 7.8% rise following the start of its BPL-003 Phase 3 program and CervoMed’s premarket jump after a director-linked trust purchased $3 million in units, following a recent $10.5 million private placement.
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
···
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals shares fell 8% to $19.68 in premarket trading Wednesday after announcing a $150 million stock-and-warrant offering. The drop follows a 167% surge Tuesday on positive Phase 1 data for soquelitinib in atopic dermatitis. Corvus paused its $100 million at-the-market share sales facility ahead of the new deal. No severe adverse events were reported in the trial.
21 January 2026
···
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK’s U.S.-listed shares fell 1.2% to $47.65 premarket after it agreed to buy RAPT Therapeutics for $2.2 billion, paying a 65% premium for rights to a mid-stage food allergy drug. The deal, led by new CEO Luke Miels, comes as GSK faces pressure to offset losses from expiring HIV drug patents. Pfizer will exit the ViiV Healthcare joint venture, with Shionogi raising its stake to 21.7%.
21 January 2026
···
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix Pharmaceuticals shares fell 7.7% to A$10.61 at Wednesday’s close after the company reported unaudited FY2025 revenue in line with guidance and noted early momentum for Gozellix. China’s drug regulator accepted the Illuccix application, triggering a formal review. Investors weighed ongoing U.S. regulatory developments and recent clinical trial results.
21 January 2026
··
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals shares soared over 167% to $21.41 in after-hours trading Tuesday after reporting positive placebo-controlled trial results for its experimental eczema pill. The company launched a $150 million underwritten stock and warrant offering following the data release. Analysts raised price targets. About 84 million shares changed hands.
21 January 2026
··
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares slipped 0.2% to $124.68 Tuesday, outperforming a broader market drop. Bernstein reiterated its Outperform rating and $135 target, citing Yeztugo as a key 2026 driver. Florida announced steep cuts to its AIDS Drug Assistance Program, drawing criticism from advocates and raising concerns over HIV drug access.
20 January 2026
··
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck shares traded near $108.82 Tuesday after Merck and Moderna reported their personalized melanoma vaccine with Keytruda cut recurrence or death risk by 49% over five years in a phase 2b trial. The stock showed little change following the update. More data will be presented at a future medical meeting. Investors await Merck’s Feb. 3 earnings call for further details on its oncology portfolio.
20 January 2026
····
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca shares fell 4.4% to $90.23 Tuesday after the company said it will delist its American depositary shares from Nasdaq and move to a direct listing of ordinary shares on the NYSE starting February 2. The switch, set for after markets close January 30, comes as European stocks face pressure from U.S. tariff threats. AstraZeneca’s London shares also dropped 2.6%.
20 January 2026
···
Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly shares rose about 0.2% Tuesday after the FDA granted Breakthrough Therapy designation to its experimental ovarian cancer drug, sofetabart mipitecan. The stock traded near $1,040 as the broader market fell 1%. The designation covers patients with platinum-resistant disease who have tried other therapies. Bernstein maintained its Outperform rating and $1,300 price target.
20 January 2026
··
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
···
Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk B shares fell 2.8% Monday in Copenhagen, closing at 378.15 crowns as investors reacted to early U.S. prescription data for the new oral form of Wegovy. Around 4.7 million shares traded. U.S. prescriptions for oral Wegovy reached nearly 3,100 for the week ending Jan. 9, while overall Wegovy prescriptions dropped 11%. Full-year results are due Feb. 4.
19 January 2026
··
AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus

AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus

AstraZeneca shares fell 1.15% to 13,890 pence in London as markets reacted to President Trump’s threat of new U.S. tariffs on Britain and other European countries. The FTSE 100 closed down 0.4%. AstraZeneca announced EU validation for Enhertu and a $630 million buyout of China cell-therapy rights. Investors trimmed risk ahead of possible trade retaliation.
19 January 2026
···
Roche stock price slips in Zurich as tariff shock shakes markets — what investors watch next

Roche stock price slips in Zurich as tariff shock shakes markets — what investors watch next

Roche Holding’s non-voting equity securities fell 0.6% to 346.80 francs Monday, just below their one-year high. The drop followed global stock declines after U.S. President Donald Trump threatened tariffs on eight European nations. Investors shifted into the Swiss franc and yen. Roche will report full-year 2025 results on Jan. 29 before the market opens.
19 January 2026
··
1 … 13 14 15 16 17 … 42

Stock Market Today

  • Primary Health Properties Stock Faces Price Target Split Amid Divergent Analyst Views
    June 23, 2026, 2:48 AM EDT. Primary Health Properties (LSE:PHP) sees a fresh split in price target as analysts diverge on valuation. JPMorgan sets a baseline target at £1.05, aligning with consensus, while Kepler Cheuvreux initiates coverage with a bullish outlook. The fair value estimate remains steady at £1.15 per share. Bullish analysts view the £1.05 target as underpriced, pointing to potential gains reflecting long-term profitability. Cautious voices highlight the narrow gap between price target and fair value, suggesting limited upside without stronger company performance. Key financial assumptions-revenue growth at 8.65%, net profit margin near 87.55%, and a slight dip in the future price-to-earnings (P/E) multiple-remain stable. Investors are advised to monitor evolving analyst sentiment for shifts in valuation perspectives.

Latest articles

Amazon Stock Just Got Hit Before Prime Day — AI Spending Fears Are Back

Amazon Stock Just Got Hit Before Prime Day — AI Spending Fears Are Back

23 June 2026
Amazon shares plunged 4.75% to $232.79 as investors questioned whether the company’s massive AI and cloud spending will pay off quickly enough, just ahead of Prime Day—a key test of U.S. consumer demand—with Bank of America projecting $21.6 billion in sales for the event and analysts warning that profit quality could disappoint if shoppers focus on lower-margin essentials.
Keel Shares Hit Record—What’s Next for the Stock

Keel Shares Hit Record—What’s Next for the Stock

23 June 2026
Keel Infrastructure Corp. surged 5.9% to a 52-week high as investors bet its power sites can be converted to AI data-center leases, with shares ending at $6.66 on heavy volume; the stock’s rally now hinges on permits, construction, and landing customer contracts, while upcoming Russell 3000 index inclusion and recent $458 million convertible note financing add both opportunity and dilution risk.
Go toTop